Linden Advisors’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Linden Advisors’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,000,000	Closed	-$10.8M	–	380
2023 Q3	$10.8M	Hold	1,000,000	–	–	0.11%	154
2023 Q2	$10.7M	Hold	1,000,000	–	–	0.11%	150
2023 Q1	$10.4M	Hold	1,000,000	–	–	0.11%	137
2022 Q4	$10.3M	Hold	1,000,000	–	–	0.11%	133
2022 Q3	$10M	Hold	1,000,000	–	–	0.09%	141
2022 Q2	$10M	Hold	1,000,000	–	–	0.09%	138
2022 Q1	$9.88M	Buy	+1,000,000	New	+$9.87M	0.06%	200

Linden Advisors's BIOS Position: Q4 2023 in Review

Linden Advisors sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q4 2023, closing a stake of 1,000,000 shares — an estimated $10.8M sold.

Linden Advisors first reported a position in BIOS in Q1 2022 and held it in 7 quarters. The position peaked at $10.8M in Q3 2023. 0 funds tracked by Wall St. Rank hold BIOS as of Q4 2023.

Linden Advisors reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Linden Advisors sold 1,000,000 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q4 2023, an estimated $10.8M.
Linden Advisors first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 7 quarters.
Linden Advisors's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $10.8M in Q3 2023.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q4 2023.

Based on Linden Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.